In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography

Mov Disord. 2017 Jun;32(6):922-927. doi: 10.1002/mds.26961. Epub 2017 Mar 3.

Abstract

Background: Alzheimer's disease copathology is common in PD at autopsy. In non-PD subjects with mild cognitive impairment, tau depositions can be detected using 18F-AV-1451 PET. We hypothesized that 18F-AV-1451 PET would show tau aggregation in PD with mild cognitive impairment and correlate with cognitive dysfunction.

Objectives: To describe tau aggregation in PD patients.

Methods: Twenty-six PD patients and 23 controls had 18F-AV-1451 PET and neuropsychological assessment to detect mild cognitive impairment.

Results: Nine PD patients (35%) were identified with mild cognitive impairment. Regional analyses showed no significant differences between groups. Voxel-wise analyses showed no correlation with cognitive domain z-scores within patients. One patient with mild cognitive impairment was estimated Braak tau stage 5; all other patients were stage 0.

Conclusion: Our results indicate that tau pathology, as detected by 18F-AV-1451, is uncommon in PD with mild cognitive impairment and shows no significant correlation with cognitive dysfunction at this stage. © 2017 International Parkinson and Movement Disorder Society.

Keywords: AV-1451; MCI; Parkinson's disease; Tau; imaging.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carbolines*
  • Cognitive Dysfunction / diagnostic imaging
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / metabolism*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / complications
  • Parkinson Disease / diagnostic imaging
  • Parkinson Disease / metabolism*
  • Positron-Emission Tomography / methods*
  • tau Proteins / metabolism*

Substances

  • Carbolines
  • tau Proteins
  • 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole